4 hours ago
https://www.psychologytoday.com/us/blog/...the-opioid
INTRO: Ibogaine is a psychoactive alkaloid found in the root bark of Tabernanthe iboga, a shrub native to Central and West Africa. For generations it has been used in Bwiti spiritual and initiation ceremonies in Gabon and neighboring regions. Ibogaine produces a profound long-lasting psychedelic state, potentially 24-48 hours. Many describe the dream-like experience as a personal “life review."
In the late 20th century, people began to notice something remarkable: some individuals who took ibogaine reported that their opioid or cocaine cravings dramatically decreased, and that withdrawal symptoms were blunted or even temporarily absent. This kicked off decades of underground use and small research programs looking at ibogaine as a potential “anti-addiction” medicine.
In the United States, ibogaine is currently a Schedule I substance—classified as having “no accepted medical use” and a high potential for abuse. It is not FDA-approved for any indication. Most treatment with ibogaine today happens in clinics in Mexico, Canada, Brazil, and a few other countries with more permissive laws.
Trump's new executive order, passed April 18, 2026, is removing legal impediments from studying psychedelics like ibogaine. The executive order is also prioritizing rescheduling and expanding use under the "Right to Try" law for treatment-resistant conditions. Supporters of ibogaine are hoping that in the near future, people won't have to travel outside the country to obtain this potentially life-saving treatment... (MORE - details)
INTRO: Ibogaine is a psychoactive alkaloid found in the root bark of Tabernanthe iboga, a shrub native to Central and West Africa. For generations it has been used in Bwiti spiritual and initiation ceremonies in Gabon and neighboring regions. Ibogaine produces a profound long-lasting psychedelic state, potentially 24-48 hours. Many describe the dream-like experience as a personal “life review."
In the late 20th century, people began to notice something remarkable: some individuals who took ibogaine reported that their opioid or cocaine cravings dramatically decreased, and that withdrawal symptoms were blunted or even temporarily absent. This kicked off decades of underground use and small research programs looking at ibogaine as a potential “anti-addiction” medicine.
In the United States, ibogaine is currently a Schedule I substance—classified as having “no accepted medical use” and a high potential for abuse. It is not FDA-approved for any indication. Most treatment with ibogaine today happens in clinics in Mexico, Canada, Brazil, and a few other countries with more permissive laws.
Trump's new executive order, passed April 18, 2026, is removing legal impediments from studying psychedelics like ibogaine. The executive order is also prioritizing rescheduling and expanding use under the "Right to Try" law for treatment-resistant conditions. Supporters of ibogaine are hoping that in the near future, people won't have to travel outside the country to obtain this potentially life-saving treatment... (MORE - details)